Scholarlink

Aim <p>This study evaluates the efficacy of a low-glycemic-index diet (LGID) in improving neurodevelopmental and sleep outcomes in pediatric Angelman Syndrome (AS) patients.</p> Method <p>A prospective, evaluator-blinded cohort study was conducted with 20 pediatric patients (3–16&#xa0;years) diagnosed with AS. Patients were assigned to an LGID or habitual diet group and followed for 24&#xa0;weeks. The primary outcome was neurodevelopmental progress measured using the Bayley Scales of Infant and Toddler Development-III. Secondary outcomes included adaptive behavior (Vineland-II), gross motor function (GMFM-88), sleep quality (actigraphy and questionnaires), seizure frequency and a 30-min awake video-EEG.</p> Results <p>At 24&#xa0;weeks, the LGID group showed a trend toward improvement in cognitive and language domains, although differences were not statistically significant (<i>p</i> &gt; 0.05). Qualitative EEG improvement was observed in 44% of LGID patients versus 25% in the control group. Sleep parameters showed minor changes, with no significant differences between groups.</p> <p>Interpretation: While the LGID was well-tolerated and showed trends toward neurocognitive and seizure improvements, results were not statistically significant. Further studies with larger sample sizes are needed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and tolerability of a low-glycemic-index ketogenic diet in Angelman syndrome: findings from the DIANE study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月21日

查看全文
  • Gema Iglesias Escalera,
  • Rosario Cazorla Calleja,
  • María Lorenzo Ruiz,
  • Julián Lara Herguedas,
  • Carolina Gutiérrez Junquera,
  • María Luz Cilleruelo Pascual,
  • Antonio F. Caballero-Bermejo,
  • Enriqueta Roman-Riechmann,
  • Samuel Ignacio Pascual Pascual,
  • Belén Ruiz-Antorán

摘要

Aim

This study evaluates the efficacy of a low-glycemic-index diet (LGID) in improving neurodevelopmental and sleep outcomes in pediatric Angelman Syndrome (AS) patients.

Method

A prospective, evaluator-blinded cohort study was conducted with 20 pediatric patients (3–16 years) diagnosed with AS. Patients were assigned to an LGID or habitual diet group and followed for 24 weeks. The primary outcome was neurodevelopmental progress measured using the Bayley Scales of Infant and Toddler Development-III. Secondary outcomes included adaptive behavior (Vineland-II), gross motor function (GMFM-88), sleep quality (actigraphy and questionnaires), seizure frequency and a 30-min awake video-EEG.

Results

At 24 weeks, the LGID group showed a trend toward improvement in cognitive and language domains, although differences were not statistically significant (p > 0.05). Qualitative EEG improvement was observed in 44% of LGID patients versus 25% in the control group. Sleep parameters showed minor changes, with no significant differences between groups.

Interpretation: While the LGID was well-tolerated and showed trends toward neurocognitive and seizure improvements, results were not statistically significant. Further studies with larger sample sizes are needed.